Lung Cancer Patient/Activist Janet Freeman-Daily talks about the successes of targeted therapies and immunotherapies in lung cancer. From a personal standpoint, her treatment with crizotinib has allowed her to survive with no evidence of cancer for four years. Her talk at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria discusses patient access to molecular testing and novel therapies, and how this can be solved.
The successes of novel therapies and molecular testing in lung cancer and patient access
